Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 498 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Acid Reflux Clear all
Completed Not applicable Interventional Results available

Neonatal Gastro-Esophageal Reflux Disease (GERD) Management Trial

NCT02486263
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Study Arm - acid suppression plus feeding bundle, Conventional arm - acid suppression only
Other
Lead sponsor
Sudarshan Jadcherla
Other
Eligibility
34 Weeks to 60 Weeks
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Not applicable Interventional Results available

COMPASSION - COngenital Multicenter Trial of Pulmonic VAlve Regurgitation Studying the SAPIEN InterventIONal THV

NCT00676689
View directory record Official record
Conditions
Pulmonary Valve Insufficiency, Pulmonary Regurgitation, Dysfunctional RVOT Conduit, Pulmonary Obstruction, Pulmonary Stenosis
Interventions
SAPIEN Transcatheter Valve Implantation
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
7
States / cities
Los Angeles, California • Miami, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Phase 3 Interventional Results available

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

NCT00658528
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Rabeprazole sodium, Esomeprazole
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,061 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Not applicable Interventional

Clinical Applications of Domperidone in Patients With Delayed Gastric Emptying

NCT01844622
View directory record Official record
Conditions
Digestive System Disease
Interventions
Domperidone
Other
Lead sponsor
Mt. Sinai Medical Center, Miami
Other
Eligibility
12 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
2
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Phase 3 Interventional Results available

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)

NCT00658632
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Rabeprazole sodium, Esomeprazole
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
85
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 73 more
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Oct 19, 2026, 5:30 PM EDT
Not listed No phase listed Observational

Management of Esophagitis Following Repair of Esophageal Atresia

NCT03619408
View directory record Official record
Conditions
Esophageal Atresia, Esophagitis
Interventions
Antacids
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
30 Days to 17 Years
Enrollment
50 participants
Timeline
2019 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2021 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease

NCT04799158
View directory record Official record
Conditions
Non-Erosive Gastro-Esophageal Reflux Disease, Heartburn
Interventions
Vonoprazan, Placebo
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
63
States / cities
Anniston, Alabama • Athens, Alabama • Huntsville, Alabama + 55 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Phase 3 Interventional

Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.

NCT05267613
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
Nexium 20mg, Nexium 10mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
1 Year to 11 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
11
States / cities
Mobile, Alabama • Sacramento, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Phase 3 Interventional

Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).

NCT00171418
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Tegaserod
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Timeline
2003 – 2005
U.S. locations
2
States / cities
Metairie, Louisiana • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 28, 2008 · Synced Oct 19, 2026, 5:30 PM EDT
Recruiting Not applicable Interventional

GERD in Children With Cystic Fibrosis

NCT06617013
View directory record Official record
Conditions
GERD in Children, Cystic Fibrosis in Children
Interventions
Discontinuation of GERD therapy
Other
Lead sponsor
Duke University
Other
Eligibility
2 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)

NCT02637557
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
IW-3718, Matching Placebo, PPI
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
62
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 19, 2026, 5:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Survey Study on Barrett's Esophagus Screening

NCT04408105
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Barrett's Esophagus, Esophagus Adenocarcinoma
Interventions
Primary Care Provider Survey, Gastroenterologist Survey, Patient Survey
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years
Enrollment
725 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
7
States / cities
Aurora, Colorado • Philadelphia, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 19, 2026, 5:30 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus

NCT00431756
View directory record Official record
Conditions
Barrett Esophagus, Esophageal Neoplasm, Gastroesophageal Reflux
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 95 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn

NCT00251745
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Dexlansoprazole MR, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
908 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
95
States / cities
Alabaster, Alabama • Birmingham, Alabama • Huntsville, Alabama + 92 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2011 · Synced Oct 19, 2026, 5:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Correlation of Oropharyngeal Pepsin and Gastroesophageal (GE) Reflux

NCT01091805
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 19, 2026, 5:30 PM EDT
Withdrawn Not applicable Interventional

HRIM vs Mucosal Impedance in GERD Participants

NCT02812407
View directory record Official record
Conditions
Gastro-esophageal Reflux Disease (GERD)
Interventions
Mucosal Impedance
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 19, 2026, 5:30 PM EDT
Completed No phase listed Observational

The Evaluation of Patients With Esophageal and Foregut Disorders With WATS (Wide Area Transepithelial Sample With 3-Dimensional Computer-Assisted Analysis) vs. 4-Quadrant Forceps Biopsy

NCT03859557
View directory record Official record
Conditions
GERD, Barrett Esophagus, Low Grade Esophageal Glandular Dysplasia, Esophageal Diseases
Interventions
Not listed
Lead sponsor
CDx Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
1,032 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease

NCT05890001
View directory record Official record
Conditions
Non-erosive Reflux Disease, Erosive Esophagitis
Interventions
BLI5100
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
18 Years to 85 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
60
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 19, 2026, 5:30 PM EDT
Recruiting Phase 2 Interventional

Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough

NCT05110144
View directory record Official record
Conditions
Refractory Chronic Cough
Interventions
Duloxetine 30 MG, Duloxetine 60 MG, Amitriptyline 25 MG, Amitriptyline 50 MG, Placebo 30 MG, Placebo 60 MG
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 19, 2026, 5:30 PM EDT
Terminated No phase listed Observational

Gastric Accommodation and Gastroesophageal Reflux

NCT01078064
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Not listed
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
1 Year to 30 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms

NCT00703534
View directory record Official record
Conditions
GERD, Acid Reflux Disease, Heartburn, Regurgitation
Interventions
AZD3355, Placebo, Gelusil®
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
84
States / cities
Athens, Alabama • Tucson, Arizona • Little Rock, Arkansas + 81 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2011 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Phase 1 Interventional

Do Acid Sensing Ion Channels Contribute to Heartburn?

NCT01095133
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Heartburn
Interventions
Amiloride, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 59 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 20, 2012 · Synced Oct 19, 2026, 5:30 PM EDT
Recruiting No phase listed Observational

Endoscopic Bariatric Therapies (EBTs): A Retrospective and Prospective Multicenter Registry

NCT04494048
View directory record Official record
Conditions
Obesity, Weight Loss, Gastro Esophageal Reflux, Bariatric Surgery Candidate
Interventions
Endoscopic Bariatric Therapies
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 89 Years
Enrollment
9,999 participants
Timeline
2016 – 2035
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 19, 2026, 5:30 PM EDT
Not listed Not applicable Interventional

Novel Endoluminal Clinical TreAtment of Reflux

NCT03090607
View directory record Official record
Conditions
GERD
Interventions
Aluvra™, Saline
Device · Drug
Lead sponsor
Impleo Medical Inc.
Industry
Eligibility
22 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
10
States / cities
Los Angeles, California • Palo Alto, California • Englewood, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 19, 2026, 5:30 PM EDT